Meeting Highlights

Patients with newly diagnosed glioblastoma who have the best chance of responding to temozolomide can be selected via a prognostic marker that has been incorporated into a commercial assay.

The assay looks in the brain tumor for MGMT (O6-methylguanine-DNA methyltransferase), which is a key DNA repair enzyme produced by the MGMT gene. High levels of MGMT are associated with lesser response to DNA-damaging therapies such as temozolomide.

Ira Finegold, MDWill sublingual immunotherapy (SLIT) ever come to the United States? Very probably, said Ira Finegold, MD, Chief of Allergy, St Luke’s- Roosevelt Hospital Center, and Clinical Professor of Medicine at Columbia University, NY.

Nasal congestion, sneezing, itching, and rhinorrhea are all characteristic of allergic rhinitis (AR). Results of 2 current studies with a total of 1260 patients with seasonal AR showed that the investigational nasal aerosol ciclesonide hydrofluoroalkane (CIC-HFA)—delivered via metered dose inhaler—is safe and very effective for treating these symptoms.

Eli O. Meltzer, MDTwo post-hoc analyses of data on patients with allergic rhinitis (AR) have uncovered new performance markers for ciclesonide aqueous nasal spray (CIC-AQ), said lead investigator Eli O. Meltzer, MD, of the Allergy and Asthma Medical Group and Research Center, San Diego, at ACAAI 2010.

Mark Dykewicz, MDApooled analysis of 1812 patients with seasonal allergic rhinitis (AR) showed that 15 days of therapy with once-daily mometasone furoate nasal spray provided 24-hour symptom relief of nasal congestion/stuffiness, said Mark Dykewicz, MD, of Wake Forest University School of Medicine, Winston- Salem, NC, who presented the results in a poster session.

Harold S. Nelson, MDSome of the year’s most significant scientific research was reviewed by Harold S. Nelson, MD, Professor of Medicine at National Jewish Health, Denver, CO. The studies showed considerable advances in subcutaneous immunotherapy, allergen extract application by patch, and the mechanisms of subcutaneous and sublingual immunotherapy (SLIT), to name a few.

Thomas Casale, MDFor anyone who fears that sublingual immunotherapy (SLIT) will be the final frontier of immunotherapy, Thomas Casale, MD, Chief of Allergy, Creighton University, Omaha, NE, says, think again. A number of other exciting novel agents are in development.

At the 2010 meeting of the American College of Chest Physicians, American Health & Drug Benefits asked Dr Hanania to weigh in on the current and emerging therapies for chronic obstructive pulmonary disease (COPD).

Page 1 of 4
Results 1 - 10 of 38
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME